Physician profile
James Worry
NPI 1063791275
$13,140.97
in general payments reported to CMS, 2019-2025
33 companies · $2,428 in 2025
The $2,428 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,791 · 2022: $2,370 · 2023: $1,798 · 2024: $1,754 · 2025: $2,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,880 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,879.54 |
| Education | $100.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,428.63 | 2021-2025 | |
| Leo Pharma INC. | $1,156.49 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $960.21 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $933.66 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $840.20 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $684.47 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $665.13 | 2021-2025 | |
| Janssen Biotech, INC. | $575.71 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $574.18 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $505.60 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $465.15 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $398.31 | 2021-2025 | Winlevi |
| Abbvie INC. | $365.69 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $352.84 | 2021-2025 | Dupixent |
| Journey Medical Corporation | $291.13 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $120.34 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $103.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Mayne Pharma Commercial LLC | $93.97 | 2021-2025 | |
| Nabriva Therapeutics, Plc | $81.40 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $56.31 | 2022-2024 | Nuzyra |
| Convatec INC. | $52.27 | 2024 | |
| Mimedx Group, INC. | $49.83 | 2024 | |
| Integra Lifesciences Corporation | $49.46 | 2024 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Almirall LLC | $41.17 | 2022-2023 | Seysara |
| Genentech USA, INC. | $36.88 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $34.99 | 2021 | |
| Organon LLC | $34.90 | 2025 | Vtama |
| Polynovo North America LLC | $21.77 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.76 | 2025 | Jublia, Cabtreo |
| Dermavant Sciences, INC. | $16.79 | 2022 | |
| Boston Scientific Corporation | $16.54 | 2025 | Watchman Flx |
| Mission Pharmacal Company | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Worry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.